Clinical-stage programs for hematological and solid tumor indications as well as autoimmune diseases
Who we are
Autolus applies extensive programming capabilities to develop advanced autologous T cell therapies that have the potential to deliver life-changing therapies to patients with cancer and autoimmune diseases and is building a fully integrated, next-generation CAR T company
About usOur Technology
Chimeric Antigen Receptors
We use Chimeric Antigen Receptors (CARs) to reprogram our T cell product candidates. These receptors combine the tumor recognition domain of an antibody with the activation and costimulatory domains from the T cell receptor to rearm a patient’s T cells to recognize and kill their cancer cells.
Advanced Cell Programming
Autolus is applying its extensive cell programming capability to develop a pipeline of precise, controlled and highly active products.
T Cell Manufacturing
We have developed our own proprietary viral vector and semi-automated cell manufacturing processes to engineer a patient's T cells with the CAR and other advanced cell programing modules.
New England Journal of Medicine
November 27 2024
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia
Life at Autolus
Whilst working at Autolus you will enjoy a flexible, diverse and dynamic working environment which actively promotes creativity, leadership and teamwork – together we are ONE Autolus.
Careers at Autolus
Investors
Autolus is building a fully-integrated, next generation CAR T company. It is committed to the development and commercialization of obe-cel in r/r Adult ALL and is progressing opportunities for obe-cel in additional indications alongside its preclinical and clinical pipeline for hematological malignancies and solid tumors.
View investor information